Oral treprostinil improved 6MWD by 16 meters at week 16 compared to baseline, demonstrating safety and efficacy in patients with PAH on background dual therapy.
RCT (n=661)
Double-blind
null
Yes
Does oral treprostinil improve 6-minute walk distance and risk status in patients with pulmonary arterial hypertension on background monotherapy or dual therapy?
Oral treprostinil provides similar improvements in 6-minute walk distance and risk status for PAH patients regardless of whether they are on background monotherapy or dual therapy.
Effect estimate: null (95% CI null)
p-value: p=0.85
ClinicalTrials.gov identifier, NCT00325442 and NCT00887978.
Lachant et al. (Mon,) conducted a rct in Pulmonary Arterial Hypertension (n=661). Oral Treprostinil vs. Placebo was evaluated on Change in 6-min walk distance (6MWD) at week 16 compared with baseline (null, 95% CI null, p=0.85). Oral treprostinil improved 6MWD by 16 meters at week 16 compared to baseline, demonstrating safety and efficacy in patients with PAH on background dual therapy.